Elizabeth Jungman directs Pew’s work on drug safety and innovation, overseeing Pew’s initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse. Before joining Pew, she served as a senior health policy adviser with the Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures. Before moving to the Hill, Jungman was in private legal practice, where she counseled clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She has an undergraduate biology degree from Harvard College, a J.D. from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. According to a Centers for Disease Control and Prevention report, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 23,000 of them die.1 Doctors routinely encounter patients with infections that do not respond to available treatment, and when new... Read More
As of September 2014, there are at least 38 new antibiotics with the potential to treat serious bacterial infections in clinical development for the U.S. market. The success rate for drug development is low; at best, only 1 in 5 candidates that enter human testing will be approved for patients. Read More
The President’s Council of Advisors on Science and Technology (PCAST) released a report to the president Sept. 18 recommending steps the federal government can take to combat antibiotic resistance. Read More